Declining Efficacy of Moxifloxacin for Mycoplasma genitalium Infection: Time for Fluoroquinolone Resistance–Guided Therapy?
The Journal of Infectious Diseases · 03.08.2026 · 234 (1) · e151-e159
DOI: 10.1093/infdis/jiag251 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 08.05.2026. Verfasst von Laura G Matthews und 10 weiteren Autor:innen. Beteiligte Einrichtung: Melbourne Sexual Health Centre, Bayside Health, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Moxifloxacin, Mycoplasma genitalium, Anti-Bacterial Agents, Mycoplasma Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Health and Medical Research Council, Australian Research Council Industrial Research Translation Hub, Australian Government Department of Higher Education.
Abstract (Originalsprache)
Background
We assessed trends in moxifloxacin use and efficacy for Mycoplasma genitalium over a decade at Melbourne Sexual Health Centre (MSHC). Specific M. genitalium mutations, namely ParC-S83I, have been associated with moxifloxacin failure. In 2024 MSHC introduced ParC-S83 testing, recommending moxifloxacin for ParC-S83 wild type infections and alternative regimens if the ParC-S83I mutation was detected. We present preliminary impacts of ParC-S83 testing on moxifloxacin use and efficacy.
Methods
Clients with M. genitalium from 2015 to 2024 were treated with doxycycline preceding macrolide resistance–guided azithromycin or moxifloxacin. Clients with a test of cure 14–90 days after completing moxifloxacin who reported > 50% adherence and no condomless sex prior to test of cure were eligible for efficacy analyses. Proportions with 95% CIs were calculated for moxifloxacin use and efficacy, with trends assessed by logistic regression. Moxifloxacin use and efficacy were compared in the 12 months before and after introduction of the ParC-S83 assay.
Results
From 2015 to 2024, 2611 of 5739 M. genitalium infections received moxifloxacin. Moxifloxacin use increased from 6.7% (n = 19/282; 95% CI, 4.1%–10.3%) in 2015 to 60.3% (n = 482/800; 95% CI, 56.8%–63.7%) in 2023 (Ptrend < .0001). Efficacy analyses included 1623 infections. Moxifloxacin efficacy decreased from 100% (n = 11/11) in 2015 to 79.3% (n = 238/300; 95% CI, 74.3%–83.8%) in 2023 (Ptrend = .007). After introduction of the ParC-S83 assay, moxifloxacin use decreased from 60.3% (n = 482/800; 95% CI, 56.8%–63.7%) in 2023 to 49.2% (n = 438/890; 95% CI, 45.9%–52.6%) in 2024 (P < .0001) and cure increased from 79.3% (n = 238/300; 95% CI, 74.3%–83.8%) in 2023 to 89.2% (n = 116/130; 95% CI, 82.6%–94.0%; P = .013) in ParC-S83 wild type infections.
Conclusions
Increasing moxifloxacin use and declining efficacy reflects rising resistance in our region. Preliminary data suggest a ParC-S83 assay has the potential to improve moxifloxacin use and cure in this setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Melbourne Sexual Health Centre, Bayside Health, Melbourne, Victoria, Australia.
- School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
- Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.
- Department of Obstetrics, Gynaecology, and Newborn Health, The University of Melbourne, Parkville, Victoria, Australia.
- Centre for Women's Infectious Diseases, The Royal Women's Hospital, Parkville, Victoria, Australia.
- Microbiological Diagnostic Unit Public Health Laboratory, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria, Australia.
ORCID-Profile: Laura G Matthews, Lenka A Vodstrcil, Natasha L Wild, Erica L Plummer, Kay Htaik, Gerald L Murray, Michelle Sait, Norelle Sherry
Förderung
- National Health and Medical Research Council
- Australian Research Council Industrial Research Translation Hub
- Australian Government Department of Higher Education
- Royal Australasian College of Physician
Zitieren
APA
Matthews, L. G., Vodstrcil, L. A., Wild, N. L., Plummer, E. L., Aguirre, I., Htaik, K., Murray, G. L., De Petra, V., Sait, M., Sherry, N., & Bradshaw, C. S. (2026). Declining Efficacy of Moxifloxacin for Mycoplasma genitalium Infection: Time for Fluoroquinolone Resistance–Guided Therapy?. The Journal of Infectious Diseases, 234(1), e151-e159. https://doi.org/10.1093/infdis/jiag251
Vancouver
Matthews LG, Vodstrcil LA, Wild NL, Plummer EL, Aguirre I, Htaik K, et al. Declining Efficacy of Moxifloxacin for Mycoplasma genitalium Infection: Time for Fluoroquinolone Resistance–Guided Therapy?. The Journal of Infectious Diseases. 2026;234(1):e151-e159. doi:10.1093/infdis/jiag251
BibTeX
@article{Matthews2026,
author = {Matthews, Laura G and Vodstrcil, Lenka A and Wild, Natasha L and Plummer, Erica L and Aguirre, Ivette and Htaik, Kay and Murray, Gerald L and De Petra, Vesna and Sait, Michelle and Sherry, Norelle and Bradshaw, Catriona S},
title = {Declining Efficacy of Moxifloxacin for Mycoplasma genitalium Infection: Time for Fluoroquinolone Resistance–Guided Therapy?},
journal = {The Journal of Infectious Diseases},
year = {2026},
volume = {234},
number = {1},
pages = {e151--e159},
doi = {10.1093/infdis/jiag251}
}
EUVIMED